semaglutide coronary artery disease Insights into cardiovascular research: Mechanisms, trials, and frontiers Cardiovascular outcomes of semaglutide and

10-Meal GLP-1 Friendly Starter Pack

For a patient experiencing persistent nausea after 2 years on Ozempic, the primary strategies are: reduce meal sizes, limit alcohol and carbonated beverages,...

Personalized wellness treatments designed to support energy, longevity, and overall health.

Tirzepatide was originally designed for type 2 diabetes, but clinical research shows significant weight loss in people without diabetes

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving 30% weight loss